Lisata Therapeutics (NASDAQ:LSTA) Releases Earnings Results, Beats Estimates By $0.21 EPS

Lisata Therapeutics (NASDAQ:LSTA) released its quarterly earnings data on Thursday. The company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.21, Zacks reports. The business had revenue of $1.00 million for the quarter.

Lisata Therapeutics Price Performance

Shares of NASDAQ:LSTA traded down $0.04 during midday trading on Friday, reaching $2.36. The company had a trading volume of 6,162 shares, compared to its average volume of 57,017. The stock has a market capitalization of $19.81 million, a P/E ratio of -0.94 and a beta of 1.14. Lisata Therapeutics has a one year low of $2.19 and a one year high of $4.20. The stock’s fifty day moving average price is $2.96 and its 200-day moving average price is $2.92.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Lisata Therapeutics in a research report on Wednesday, December 11th.

About Lisata Therapeutics

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.